Jan 4, 2017

IQWiG’s results on AMNOG at a glance

Press releases for dossier assessments only in special cases

So far the German Institute for Quality and Efficiency in Health Care (IQWiG) has published a press release for each dossier assessment, except for orphan drugs. The same applied to all addenda in which the conclusion differed from that of the preceding dossier assessment. Since the German Act on the Reform of the Market for Medicinal Products (AMNOG) became effective in 2011, the number of press releases by the Institute has continuously increased.

Since 2 January 2017, IQWiG publishes press releases only for selected dossier assessments. To nevertheless enable the press and other interested parties to gain a rapid overview of all AMNOG assessment results, an overview in the form of a table is published in the press centre on the IQWiG website. It includes the drug assessed, its therapeutic indication, and the main results of the assessment.

The table is linked to the project documents to provide more detailed information, for example, on the research questions investigated, the appropriate comparator therapies, the target populations, or on how the result of the benefit assessment was inferred from the advantages and disadvantages of the drug in respect of patient-relevant outcomes (e.g. side effects or health-related quality of life).

Further information:

  • IQWiG’s overview of AMNOG results

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form